Recruiting
NCT05336383: Phase 2: Phase II Study of Salvage Radiation Treatment After BCMA CART Therapy for RRMM
Updated: Feb 5
NCT05336383: Phase 2: Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
This study is a Phase II study to determine the preliminary safety and efficacy of salvage radiation treatment after BCMA CAR-T therapy in subjects with RRMM.
Sponsor
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT05336383
Official Title: Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
First Posted : April 20, 2022
Click here to see details on ClinicalTrials.gov
Drug: Radiation Therapy
Location
United States, Texas